Healthcare costs figure strongly in California’s affordability crisis, with nearly 1 million Californians going to Mexico each year to purchase more affordable medical care and prescription drugs. To ...
HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced an expansion of TrumpRx.gov to provide unprecedented price transparency and choice on generic ...
Lupin is increasing its focus on complex generics, specialty medicines and differentiated products as global patent expiries create opportunities in regulated markets. The company reported growth in ...
Novo Nordisk is losing GLP-1 and diabetes market share in key regions as Eli Lilly's Zepbound and Mounjaro gain U.S. leadership. NVO's latest GLP-1 drug delivered weaker weight loss than Eli Lilly's, ...
Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams March 31 (Reuters) - Novo Nordisk on Tuesday cut the prices of its ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy ...
After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results